다발성 경화증 : 시장 인사이트, 역학 및 시장 예측(2036년)

Multiple Sclerosis (MS) Insights and Trends

• According to DelveInsight's analysis, the MS market across the 7MM was valued at approximately USD 22 billion in 2025 and is projected to expand at a Compound Annual Growth Rate of 3.5%, reflecting steady growth driven by the anticipated entry of advanced therapies and improved clinical management.
• In 2025, the United States accounted for approximately 950,000 diagnosed prevalent cases of MS, while the total cases across the 7MM reached 1,700,000 cases, representing a substantial patient base driving the demand for advanced disease-modifying therapies (DMTs).
• Current FDA-approved DMTs, such as ocrelizumab (OCREVUS) by Roche, alemtuzumab (LEMTRADA) by Sanofi, siponimod (MAYZENT) by Novartis, diroximel fumarate (VUMERITY) by Biogen, and cladribine (MAVENCLAD) by Merck KGaA, focus on controlling inflammatory mechanisms to reduce relapses and delay disability. These therapies are tailored to various stages of MS to improve long-term patient outcomes.
• Roche, Sanofi, Novartis, and AB Science, among others are progressing their assets through various clinical trial phases, driving innovation in the MS market and creating significant growth opportunities.
• The MS pipeline is robust, transitioning toward innovative mechanisms that address both inflammation and neurodegeneration. Key investigational candidates include remibrutinib (LOU064) by Novartis, frexalimab (SAR441344) by Sanofi, tolebrutinib (SAR442168) by Sanofi, and vidofludimus calcium (IMU-838) by Immunic Therapeutics, signaling a shift toward more effective, next-generation interventions.
• While MS cannot yet be cured, various treatments are available to reduce the frequency and intensity of relapses and to slow long-term disease progression. For managing acute relapses, corticosteroids are the standard approach-most notably IV methylprednisolone, which is widely used to shorten the duration and impact of flare-ups.
• Significant treatment gaps persist, notably around diagnostic challenges and misdiagnosis. Accurate diagnosis remains complex due to nonspecific symptoms and over interpretation of Magnetic Resonance Imaging data. Limited awareness and access to specialized neurological care, especially advanced imaging, delay accurate diagnosis. Improving diagnostic precision is a critical unmet need to ensure appropriate and timely treatment initiation.

Multiple Sclerosis (MS) Market size and forecast

• 2025 MS Market Size in the 7MM: USD 22 billion
• MS Growth Rate (2026-2036) in the 7MM: 3.5% CAGR

DelveInsight's 'Multiple Sclerosis (MS) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of MS, historical and forecasted epidemiology, as well as the MS market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The MS market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, MS patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across the 7MM regions. The report highlights key unmet medical needs in MS and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Geography Covered:

North America: The United States

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan

Multiple Sclerosis (MS) Understanding and Treatment Algorithm

Multiple Sclerosis (MS) Overview and Diagnosis

MS is a lifelong and unpredictable disease that affects individuals differently. While some experience mild symptoms, others develop progressive disability, though most go through cycles of relapses and recovery. Common early signs include vision problems, muscle weakness, numbness, and balance issues, with fatigue and cognitive or mood changes emerging over time. Women are more frequently affected than men. Although MS is rarely fatal, it can significantly impact quality of life, making early diagnosis and timely treatment crucial, especially with newer therapies that can help slow disease progression.

Diagnosing MS is challenging, as there is no single definitive test. Instead, clinicians use a combination of clinical evaluation and diagnostic tools to rule out other conditions and confirm the disease. The process typically begins with a detailed medical history, physical examination, and neurological assessment to evaluate symptoms and nerve function. MRI of the brain and spinal cord plays a key role in identifying demyelinating lesions, often with the use of contrast dye to detect active inflammation. Additional tests, such as a lumbar puncture to assess cerebrospinal fluid, evoked potentials to measure nerve signal responses, and optic nerve evaluations, help strengthen the diagnosis and ensure a comprehensive assessment.

Multiple Sclerosis (MS) Treatment Landscape

Treatment of MS is guided by disease stage and severity, with current FDA-approved DMTs such as orelizumab (OCREVUS) by Roche and siponimod (MAYZENT) by Novartis primarily targeting inflammatory processes to reduce relapses and delay disability progression. While these therapies have significantly improved patient outcomes, they have limitations in fully addressing neurodegeneration and long-term disability. This has driven the development of next-generation treatments. Emerging candidates like remibrutinib (LOU064) by Novartis, frexalimab (SAR441344) by Sanofi, and vidofludimus Calcium (IMU-838) by Immunic therapeutics aim to offer more comprehensive disease control by targeting both inflammation and neurodegenerative mechanisms.

Multiple Sclerosis (MS) Unmet Needs

The section "unmet needs of MS" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of curative therapies and challenges in addressing progressive neurodegeneration

2. Absence of FDA-approved treatments with exclusivity for pediatric MS

3. Long-term disability progression

4. Diagnostic challenges and risk of misdiagnosis

5. Limited progress in biomarker development

6. Lack of approved therapies for Non-active Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis (MS) Epidemiology

Key Findings from Multiple Sclerosis (MS) Epidemiological Analysis and Forecast

• As of 2025, the diagnosed prevalent population of MS across the 7MM is estimated at approximately 1.5 million cases, reflecting the significant burden of the disease across major markets.
• The United States represents the largest share in 2025, with nearly 950,000 cases, driven by advanced diagnostics and higher disease awareness.
• The combined EU4 and the UK contribute around 700,000 cases, with the UK accounting for approximately 140,000 cases, making it the largest individual European segment in 2025.
• By 2025, females in the United States are disproportionately affected by MS, with an estimated approx. 700,000 diagnosed cases, while the number of diagnosed males is significantly lower, at around 250,000.

Multiple Sclerosis (MS) Drug Analysis & Competitive Landscape

The MS drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I to Phase III clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the MS treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the MS therapeutics market.

Approved Therapies for Multiple Sclerosis (MS)

Ocrelizumab and Hyaluronidase-ocsq (OCREVUS ZUNOVO): Roche

Ocrelizumab and Hyaluronidase-ocsq (OCREVUS ZUNOVO) is a humanized monoclonal antibody (mAb) that selectively targets CD20-positive B cells-an immune cell type believed to play a significant role in the damage of myelin and axons, which can lead to disability in individuals with MS. Preclinical studies indicate that OCREVUS binds to CD20 proteins found on specific B cells, but not on stem or plasma cells, potentially preserving essential immune functions.

• In September 2024, the US Food and Drug Administration (FDA) approved OCREVUS ZUNOVO as the first and only SC injection administered twice a year in just 10 min for adults with relapsing and progressive forms of MS.
• In April 2024, OCREVUS ZUNOVO subcutaneous formulation was introduced in the EU as the first and only twice-yearly, 10-minute injection for treating Relapsing Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS).

Multiple Sclerosis (MS) Pipeline Analysis

Tolebrutinib (SAR442168): Sanofi

It is an investigational oral Bruton's tyrosine kinase (BTK) inhibitor engineered to penetrate the brain and remain bioactive within the central nervous system, aiming to target smoldering neuroinflammation major contributor to disability progression in MS. Unlike traditional MS therapies that focus on peripheral inflammation, tolebrutinib crosses the blood-brain barrier to reach therapeutic levels in the cerebrospinal fluid, enabling it to modulate both B cells and disease-associated microglia.

• Tolebrutinib (SAR442168) is also being evaluated in the Phase III PERSEUS trial for PPMS, with results anticipated in late 2025 and a potential regulatory submission planned for 2026.
• In March 2025, the US FDA accepted tolebrutinib for priority review to treat MS, particularly non-relapsing secondary progressive MS (nrSPMS), with a decision expected by September 2025 and a parallel review underway in the EU by Sanofi.

Multiple Sclerosis (MS) Key Players, Market Leaders and Emerging Companies

• Roche
• Sanofi
• Novartis
• Biogen
• Merck KGaA
• AB Science
• Clene Nanomedicine
• InnoCare and more

Multiple Sclerosis (MS) Drug Updates

• On January 2025, National Institute for Health and Care Excellence (NICE) approved natalizumab, administered via injection or infusion, for adults with RRMS.
• In January 2026, the US FDA approved a generic glatiramer acetate injection for the treatment of MS, expanding access to more affordable therapy options for patients.
• In February 2026, Roche announced that its fenebrutinib met its primary endpoint in a late-stage clinical trial for the treatment of MS.

Multiple Sclerosis (MS) Market Outlook

MS is the most common primary demyelinating disease of the CNS, with the potential to progress to significant neurological disability. Though its pathogenesis remains unclear, current evidence suggests an autoimmune response targeting myelin antigens. Autoreactive T and B cells cross the BBB and initiate immune responses against myelin, leading to the formation of demyelinating plaques. These immune-mediated attacks result in axonal damage and neurodegeneration through both inflammatory and neurotoxic pathways within the CNS.

Key marketed therapies shaping current management

• Ocrelizumab (OCREVUS) - Roche: OCREVUS is a humanized mAb engineered to specifically target CD20-positive B cells, which are believed to play a central role in causing myelin and axonal damage-key factors contributing to disability in MS. Preclinical research suggests that OCREVUS binds to CD20 proteins on select B cells while sparing stem cells and plasma cells, potentially preserving essential immune system functions.
• Alemtuzumab (LEMTRADA) - Sanofi: A CD52-targeting cytolytic mAb, is approved for treating RRMS -including active secondary progressive MS -in patients aged 17 and older. Due to its risk profile, it is typically reserved for those who have not responded adequately to at least two prior MS therapies. LEMTRADA is not recommended for use in patients with CIS because of its safety profile.
• Siponimod (MAYZENT) - Novartis: MAYZENT is a selective modulator of sphingosine 1-phosphate (S1P) receptors, targeting S1P1 and S1P5 subtypes. By binding to the S1P1 receptor, it restricts lymphocyte exit from lymph nodes, thereby limiting their infiltration into the CNS and reducing inflammation in MS. Additionally, MAYZENT crosses the Blood Brain Barrier (BBB) and interacts with S1P5 receptors located on astrocytes and oligodendrocytes. In preclinical MS models, this engagement has demonstrated potential neuroprotective and remyelinating properties within the CNS.

And more

Overall, in MS, the launch targeted biologics, improved diagnosis through autoantibody testing, and increasing disease awareness are expected to drive steady growth in the 7MM MS market from 2022-2036, with strong commercial implications for both marketed products and emerging pipelines.

• Among the 7MM, the United States accounted for the largest MS market size, which was valued at nearly USD 18 billion in 2025.
• The most meaningful recent shift in the treatment landscape has been the focus on addressing the long-term progression of MS by shifting beyond traditional anti-inflammatory agents. While high-efficacy DMTs like ocrelizumab (OCREVUS) and ofatumumab (KESIMPTA) remain the standards of care across key markets, the emergence of next-generation candidates specifically BTK inhibitors represents a significant leap. These advanced oral agents aim to cross the BBB and modulate immune cells within the CNS to potentially slow neurodegeneration and improve long-term functional outcomes for patients.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Multiple Sclerosis (MS) (2022-2036 Forecast)

The MS treatment landscape is strategically structured between managing acute relapses with anti-inflammatory corticosteroids and long-term disease modification using various DMTs. While acute therapies focus on quick functional recovery, long-term management is essential for reducing relapse frequency and slowing disability progression. The market is increasingly shifting toward high-efficacy and innovative emerging therapies that aim to preserve neurological function and improve the overall Quality of Life (QoL) for patients through 2036.

• Monoclonal Antibodies (mAb): mAb indicated for RRMS and aSPMS, but is not recommended for CIS due to significant safety concerns. Its use is restricted under the LEMTRADA Risk Evaluation and Mitigation Strategy (REMS) Program in the US due to serious risks including autoimmunity, infusion reactions, and malignancies. Despite robust Phase III data, its utilization remains limited by its risk profile and stringent monitoring requirements. Sanofi holds global development rights, while Bayer receives sales-based royalties.
• CD20-Directed Therapies: CD20-directed therapies, such as ofatumumab (KESIMPTA), represent a significant shift toward high-efficacy B-cell depletion strategies in MS management. As a self-administered subcutaneous injection, KESIMPTA offers clinical efficacy comparable to intravenous options with the added benefit of patient convenience. Currently under Phase III investigation for pediatric RMS, it reflects the growing emphasis on individualized care by balancing potent disease control with flexible administration.

Multiple Sclerosis (MS) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the MS drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The emergence of next-generation therapies is significantly expanding the treatment paradigm in MS. A transformative asset in this space is ocrelizumab and hyaluronidase-ocsq (OCREVUS ZUNOVO), developed by Roche. This humanized mAb selectively targets CD20-positive B cells to mitigate myelin and axonal damage while preserving essential immune stem cells. By leveraging the ENHANZE drug delivery platform, it utilizes recombinant human hyaluronidase PH20 (rHuPH20) to temporarily enhance tissue permeability, allowing for efficient subcutaneous absorption. Positioned to offer patients greater administration flexibility without compromising efficacy, OCREVUS ZUNOVO is anticipated to have a Medium-Fast uptake trajectory, signaling a significant shift toward more convenient and individualized disease management.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Multiple Sclerosis (MS)

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Multiple Sclerosis (MS) therapies Price Scenario & Trends

Pricing and analogue assessment of MS therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Multiple Sclerosis (MS) Approved Drugs

Ocrelizumab (OCREVUS) - The US list price of ocrelizumab (OCREVUS), a therapy approved for the treatment of MS, is nearly USD 78,000, reflecting its status as a high-cost specialty medication used to manage both relapsing and primary progressive forms of the disease.

Industry Experts and Physician Views for Multiple Sclerosis (MS)

To keep up with MS market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the MS emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts engaged with 10+ key opinion leaders (KOLs) across major markets to capture country-level insights in MS Leading centers such as University of California and Royal College of Physicians, among others, were consulted to validate clinical practices, treatment patterns, and emerging therapeutic perspectives.

Their opinion helps understand and validate current and emerging MS, therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for Market access, therapy adoption, and pipeline prioritization in MS.

Qualitative Analysis: SWOT and Attribute Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and attribute analysis.

In the SWOT analysis of MS, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Attribute analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of MS, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the MS market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM MS market.

Report Insights

• Multiple Sclerosis (MS) Patient Population Forecast
• Multiple Sclerosis (MS) Therapeutics Market Size
• Multiple Sclerosis (MS) Pipeline Analysis
• Multiple Sclerosis (MS) Market Size and Trends
• Multiple Sclerosis (MS) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-Based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Multiple Sclerosis (MS) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by Geography)
• Multiple Sclerosis (MS) Treatment Addressable Market (TAM)
• Multiple Sclerosis (MS) Competitive Landscape
• Multiple Sclerosis (MS) Major Companies Insights
• Multiple Sclerosis (MS) Price trends and Analogue Assessment
• Multiple Sclerosis (MS) Therapies Drug Adoption/Uptake
• Multiple Sclerosis (MS) Therapies Peak Patient Share analysis

Report Assessment

• Multiple Sclerosis (MS) Current Treatment Practices
• Multiple Sclerosis (MS) Unmet Needs
• Multiple Sclerosis (MS) Clinical Development Analysis
• Multiple Sclerosis (MS) Emerging Drugs Product Profiles
• Multiple Sclerosis (MS) Market Attractiveness
• Multiple Sclerosis (MS) Qualitative Analysis (SWOT and Attribute analysis)

FAQs:

Market Insights

• What was the MS market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of MS?
• What are the disease risks, burdens, and unmet needs of MS? What will be the growth opportunities across the 7MM concerning the patient population with MS?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of MS? What are the current guidelines for treating MS in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the MS market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Multiple Sclerosis (MS) Market Overview at a Glance

• 3.1. Market Share (%) Distribution of MS by Therapies in the 7MM in 2025
• 3.2. Market Share (%) Distribution of MS by Therapies in the 7MM in 2036

4. Executive Summary

5. Key Events

6. Disease Background and Overview: MS

• 6.1. Introduction
• 6.2. Signs and Symptoms
• 6.3. Classification Systems
• 6.4. Etiology
• 6.5. Risk Factors
• 6.6. Pathogenesis
• 6.7. Pathophysiology
• 6.8. Clinical Manifestations
• 6.9. Diagnosis
  • 6.9.1. Diagnostic Algorithm
  • 6.9.2. Diagnostic Criteria
  • 6.9.3. Diagnostic Guidelines
• 6.10. Treatment
  • 6.10.1. Treatment Algorithm
  • 6.10.2. Treatment Guidelines

7. Epidemiology and Market Methodology

8. Epidemiology and Patient Population

• 8.1. Key Findings on Patient Burden in MS
• 8.2. Assumptions and Rationale: 7MM
  • 8.2.1. Diagnosed Prevalence of MS
  • 8.2.2. Gender-specific Diagnosed Prevalence of MS
  • 8.2.3. Phenotype-specific Diagnosed Prevalence of MS
  • 8.2.4. EDSS Distribution-specific Diagnosed Prevalence of MS
• 8.3. Total Diagnosed Prevalent Cases of MS in the 7MM
• 8.4. The United States
  • 8.4.1. Total Diagnosed Prevalent Cases of MS in the US
  • 8.4.2. Gender-specific Diagnosed Prevalent Cases of MS in the US
  • 8.4.3. Phenotype-specific Diagnosed Prevalent Cases of MS in the US
  • 8.4.4. EDSS-specific Diagnosed Prevalent Cases of MS in the US
• 8.5. EU4 and the UK
  • 8.5.1. Total Diagnosed Prevalent Cases of MS in EU4 and the UK
  • 8.5.2. Gender-specific Diagnosed Prevalent Cases of MS in EU4 and the UK
  • 8.5.3. Phenotype-specific Diagnosed Prevalent Cases of MS in EU4 and the UK
  • 8.5.4. EDSS-specific Diagnosed Prevalent Cases of MS in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of MS in Japan
  • 8.6.2. Gender-specific Diagnosed Prevalent Cases of MS in Japan
  • 8.6.3. Phenotype-specific Diagnosed Prevalent Cases of MS in Japan
  • 8.6.4. EDSS-specific Diagnosed Prevalent Cases of MS in Japan

9. Patient Journey

10. Marketed Therapies

• 10.1. Competitive Landscape: Marketed Drugs
• 10.2. Ocrelizumab OCREVUS: Roche
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
• 10.3. Ocrelizumab and Hyaluronidase-ocsq (OCREVUS ZUNOVO): Roche
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Clinical Trials Information
  • 10.3.4. Safety and Efficacy
• 10.4. Alemtuzumab (LEMTRADA): Sanofi
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Developmental Activities
  • 10.4.4. Clinical Trials Information
  • 10.4.5. Safety and Efficacy
• 10.5. Siponimod (MAYZENT): Novartis
  • 10.5.1. Product Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Clinical Trials Information
  • 10.5.4. Safety and Efficacy
• 10.6. Diroximel Fumarate (VUMERITY): Biogen
  • 10.6.1. Product Description
  • 10.6.2. Regulatory Milestones
  • 10.6.3. Other Developmental Activities
  • 10.6.4. Clinical Trials Information
  • 10.6.5. Safety and Efficacy
• 10.7. Cladribine (MAVENCLAD): Merck KGaA
  • 10.7.1. Product Description
  • 10.7.2. Regulatory Milestones
  • 10.7.3. Other Developmental Activities
  • 10.7.4. Clinical Trials Information
  • 10.7.5. Safety and Efficacy
• 10.8. Peginterferon Beta-1a (PLEGRIDY): Biogen
  • 10.8.1. Product Description
  • 10.8.2. Regulatory Milestones
  • 10.8.3. Other Developmental Activities
  • 10.8.4. Clinical Trials Information
  • 10.8.5. Safety and Efficacy
• 10.9. Ozanimod ZEPOSIA: Bristol Myers Squibb
  • 10.9.1. Product Description
  • 10.9.2. Regulatory Milestones
  • 10.9.3. Other Developmental Activities
  • 10.9.4. Clinical Trials Information
  • 10.9.5. Safety and Efficacy
• 10.10. Ponesimod (PONVORY): Vanda Pharmaceuticals/Juvise Pharmaceuticals
  • 10.10.1. Product Description
  • 10.10.2. Regulatory Milestones
  • 10.10.3. Other Developmental Activities
  • 10.10.4. Clinical Trials Information
  • 10.10.5. Safety and Efficacy
• 10.11. Ofatumumab (KESIMPTA): Novartis
  • 10.11.1. Product Description
  • 10.11.2. Regulatory Milestones
  • 10.11.3. Other Developmental Activities
  • 10.11.4. Clinical Trials Information
  • 10.11.5. Safety and Efficacy
• 10.12. Ublituximab-xiiy (BRIUMVI):TG Therapeutics
  • 10.12.1. Product Description
  • 10.12.2. Regulatory Milestones
  • 10.12.3. Other Developmental Activities
  • 10.12.4. Clinical Trials Information
  • 10.12.5. Safety and Efficacy
• 10.13. Monomethyl Fumarate (BAFIERTAM): Cycle Pharmaceuticals (Banner Life Sciences)
  • 10.13.1. Product Description
  • 10.13.2. Regulatory Milestones
  • 10.13.3. Other Developmental Activities
  • 10.13.4. Clinical Trials Information
  • 10.13.5. Safety and Efficacy

11. Pipeline Therapies: MS

• 11.1. Competitive Landscape: Emerging Drugs
• 11.2. Remibrutinib: Novartis
  • 11.2.1. Drug Description
  • 11.2.2. Clinical Trials Information
  • 11.2.3. Safety and Efficacy
  • 11.2.4. Analysts' Views
• 11.3. Tolebrutinib (SAR442168): Sanofi
  • 11.3.1. Drug Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analysts' Views
• 11.4. Fenebrutinib: Roche
  • 11.4.1. Drug Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Trials Information
  • 11.4.4. Safety and Efficacy
  • 11.4.5. Analysts' Views
• 11.5. Frexalimab (SAR441344): Sanofi
  • 11.5.1. Drug Description
  • 11.5.2. Other Developmental Activities
  • 11.5.3. Clinical Trials Information
  • 11.5.4. Safety and Efficacy
  • 11.5.5. Analysts' Views
• 11.6. Vidofludimus calcium (IMU-838): Immunic Therapeutics
  • 11.6.1. Drug Description
  • 11.6.2. Other Developmental Activities
  • 11.6.3. Clinical Trials Information
  • 11.6.4. Safety and Efficacy
  • 11.6.5. Analysts' Views
• 11.7. Masitinib: AB Science
  • 11.7.1. Drug Description
  • 11.7.2. Other Developmental Activities
  • 11.7.3. Clinical Trials Information
  • 11.7.4. Safety and Efficacy
  • 11.7.5. Analysts' Views
• 11.8. CNM-Au8: Clene Nanomedicine
  • 11.8.1. Drug Description
  • 11.8.2. Other Developmental Activities
  • 11.8.3. Clinical Trials Information
  • 11.8.4. Safety and Efficacy
  • 11.8.5. Analysts' Views
• 11.9. Orelabrutinib (ICP-022): InnoCare
  • 11.9.1. Drug Description
  • 11.9.2. Other Developmental Activities
  • 11.9.3. Clinical Trials Information
  • 11.9.4. Safety and Efficacy
  • 11.9.5. Analysts' Views
• 11.10. PIPE-307: Contineum Therapeutics
  • 11.10.1. Drug Description
  • 11.10.2. Other Developmental Activities
  • 11.10.3. Clinical Trials Information
  • 11.10.4. Analysts' Views

12. MS: 7MM Market Analysis

• 12.1. MS Market Key Findings and Insights
• 12.2. Key Market Forecast Assumptions
  • 12.2.1. Cost Assumptions and Rebates
  • 12.2.2. Pricing Trends
  • 12.2.3. Analogue Assessment
  • 12.2.4. Launch Year and Therapy Uptake
• 12.3. Market Outlook
• 12.4. Attribute Analysis
• 12.5. Total Market Size of MS in the 7MM
• 12.6. Market Size of MS by Therapies in the 7MM
• 12.7. Market Size of MS in the United States
  • 12.7.1. Total Market of MS
  • 12.7.2. Market Size of MS by Therapies in the United States
• 12.8. Market Size of MS in EU4 and the UK
  • 12.8.1. Total Market Size of MS
  • 12.8.2. Market Size of MS by Therapies in EU4 and the UK
• 12.9. Market Size of MS in Japan
  • 12.9.1. Total Market Size of MS
  • 12.9.2. Market Size of MS by Therapies in Japan

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. CMS
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Acronyms and Abbreviations
• 17.2. Bibliography
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight